caa a22 4500 465735355 CHVBK 20180323111753.0 cr unu---uuuuu 170327e19901001xx s 000 0 eng 10.1007/BF02427829 doi (NATIONALLICENCE)springer-10.1007/BF02427829 A cerebral glioma model for experimental therapy and in vivo invasion studies in syngeneic BD IX rats [Elektronische Daten] [Olav Mella, Rolf Bjerkvig, Baard-Christian Schem, Olav Dahl, Ole Laerum] Anin vivo glioma model was developed in syngeneic BD IX rats. The BT4An tumor was derived from serialin vivo passages of the BT4A tumor, originally induced from transformed fetal rat brain cells after transplacental exposure to ethylnitrosourea. The cell line was characterized for the presence of neuroglial differentiation markers, chromosome content and cell cycle distribution as determined by flowcytometry. A standardized method for i.c. tumor induction was developed, and the tumors were investigated by light and electron microscopy and for evidence of blood-brain barrier disruption. Tumor cell ability for phagocytosis was studied, as this property may be important for the invasion pattern of the tumors. We conclude that the model seems suitable for bothin vivo therapy and invasion studies. The tumor had 100% tumor take, yielded a predictable symptom-free life span after inoculation, had a characteristic histological picture of an aggressive glioma, and the blood-brain barrier within the tumor was in part disrupted. Compared to the parent cell line, there was loss of neuroglial differentiation markers, the chromosomal distribution was changed, and the ability for phagocytosis was practically lost. Kluwer Academic Publishers, 1990 glioma nationallicence experimental brain tumor nationallicence differentiation markers nationallicence blood-brain barrier nationallicence Mella Olav Department of Oncology, University of Bergen, N-5021 Haukeland Hospital, Bergen, Norway aut Bjerkvig Rolf The Gade Institute, Department of Pathology, University of Bergen, N-5021 Haukeland Hospital, Bergen, Norway aut Schem Baard-Christian Department of Oncology, University of Bergen, N-5021 Haukeland Hospital, Bergen, Norway aut Dahl Olav Department of Oncology, University of Bergen, N-5021 Haukeland Hospital, Bergen, Norway aut Laerum Ole The Gade Institute, Department of Pathology, University of Bergen, N-5021 Haukeland Hospital, Bergen, Norway aut Journal of Neuro-Oncology Kluwer Academic Publishers 9/2(1990-10-01), 93-104 0167-594X 9:2<93 1990 9 11060 https://doi.org/10.1007/BF02427829 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02427829 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Mella Olav Department of Oncology, University of Bergen, N-5021 Haukeland Hospital, Bergen, Norway aut NATIONALLICENCE 700 1- Bjerkvig Rolf The Gade Institute, Department of Pathology, University of Bergen, N-5021 Haukeland Hospital, Bergen, Norway aut NATIONALLICENCE 700 1- Schem Baard-Christian Department of Oncology, University of Bergen, N-5021 Haukeland Hospital, Bergen, Norway aut NATIONALLICENCE 700 1- Dahl Olav Department of Oncology, University of Bergen, N-5021 Haukeland Hospital, Bergen, Norway aut NATIONALLICENCE 700 1- Laerum Ole The Gade Institute, Department of Pathology, University of Bergen, N-5021 Haukeland Hospital, Bergen, Norway aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 9/2(1990-10-01), 93-104 0167-594X 9:2<93 1990 9 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer